Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage of selected lipid and non-lipid biomarker laboratory tests and multi-marker cardiovascular risk panels for risk assessment and management of cardiovascular disease for Blue Cross Blue Shield - Rhode Island members.
Fibrinogen activity (CPT 85384) and fibrinogen antigen (CPT 85385) are covered effective 2/1/2026 for Medicare Advantage and Commercial Products.
Measurement of cystatin C (CPT 82610) and certain lipoprotein tests (CPT 83700, 83701, 83704) are medically necessary when filed with a covered diagnosis.
Lipoprotein(a) (CPT 83695) and small dense LDL cholesterol (CPT 83722) are not covered for Medicare Advantage and are not medically necessary for Commercial Products.
Lp-PLA2 (CPT 83698) is considered not covered for Medicare Advantage and not medically necessary for Commercial Products.
B-type natriuretic peptide testing (CPT 83880) is covered but not separately reimbursed when used with standard diagnostic evaluation of acute heart failure in acute-care settings.
Commercial cardiovascular disease multi-marker risk panels and other CVD risk panels (including proprietary panels and panels reported with unlisted CPTs) are considered not covered or not medically necessary.
Coverage Determinations and Rationale
Coverage determinations for Medicare Advantage Plans and Commercial Products
Covered when described below for Medicare Advantage Plans and Commercial Products:
Coverage rationale and clinical utility conclusions — summarized coverage stance from evidence sections
Summarized coverage rationale and clinical utility conclusions from the evidence sections:
This policy specifically excludes simple lipid panels from its scope. A simple lipid panel is defined to include total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides (and certain calculated ratios) and is not governed by this policy. The policy also does not address the use of biomarker panels for the diagnosis of acute myocardial infarction; such acute diagnostic uses are outside the scope of this coverage document.
Some Commercial Products may be subject to contract exclusions that limit coverage for expanded biomarker or genetic testing per applicable state mandates (for example, the referenced Rhode Island biomarker testing mandate). For self‑funded groups or plans with such exclusions, coverage, prior authorization requirements, and which genetic testing services are covered or excluded are determined by the member's Benefit Booklet or plan documents; providers should refer to the Benefit Booklet and related policy lists for specifics.
The following CPT codes are designated as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products based on insufficient evidence: 83695 (Lipoprotein[a]), 83698 (Lp‑PLA2), and 83722 (Small dense LDL cholesterol). Claims for these listed codes will be denied as not medically necessary when billed for the referenced products.
Tests or services that are identified in the payer's Non‑Reimbursable Health Service Codes policy are excluded from reimbursement. Providers should consult the referenced payer lists and related policies (for example, Proprietary Laboratory Analyses and Unlisted Procedures) when submitting claims to confirm whether a test is non‑reimbursable.
Benefits and eligibility, including any plan‑specific coverage limitations, are determined by the member's subscriber agreement or employer agreement and the member's Benefit Booklet. If a service is determined to be not medically necessary or a non‑covered benefit, the provider may not bill the member unless the member has been informed and provided written agreement in advance. For member‑specific questions contact the provider call center.
Specific analytes and panels addressed by this policy are considered not covered or not medically necessary when listed. Examples explicitly called out include Lipoprotein(a) (CPT 83695), Small dense LDL cholesterol (CPT 83722), Lp‑PLA2 (CPT 83698), and commercially available or proprietary multi‑marker cardiovascular risk panels (for example, MI‑HEART Ceramides CPT 0119U and VAP CPT 0052U) and panels reported with unlisted CPTs. These tests are considered not covered or not medically necessary because evidence does not demonstrate that they improve clinical management or outcomes beyond traditional risk assessment.
The clinical evidence shows that while several nontraditional biomarkers (for example, HDL and LDL subclasses, Lp(a), cystatin C, and Lp‑PLA2) are associated with cardiovascular risk, there is insufficient evidence that measuring these markers in asymptomatic individuals meaningfully changes management or improves health outcomes. Trials and observational data have not established that use of these markers as treatment targets or to guide therapy results in improved net health outcomes.
This excerpt does not present an exhaustive list of every test that might be deemed not medically necessary; rather, it highlights specific codes and panel types and states the general determination principle: tests or panels for which clinical utility is not established are considered not covered or not medically necessary. Coverage determinations should follow the policy statements, coding lists, and referenced related payer policies, and providers should use prior authorization processes where applicable to confirm coverage for tests not explicitly listed.
CPT/HCPCS Coding and Status
| 82610 | Cystatin C |
| 85384 | Fibrinogen; activity |
| 85385 | Fibrinogen; antigen |
| 83695 | Lipoprotein (a) |
| 83698 | Lipoprotein-associated phospholipase A2, (Lp-PLA2) |
| 83700 | Lipoprotein, blood; electrophoretic separation and quantitation |
| 83701 | Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed |
| 83704 | Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed |
| 83722 | Lipoprotein, Direct Measurement; Small Dense LDL Cholesterol |
| 0119U | MI-HEART Ceramides, Plasma (Mayo Clinic) |
| 83700 | Lipoprotein, blood; electrophoretic separation and quantitation |
| 83701 | Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation) |
| 83704 | Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed |
| 82610 | Cystatin C |
| 83880 | Natriuretic peptide |
| 85384 | Fibrinogen; activity |
| 85385 | Fibrinogen; antigen |
| 83700 | Lipoprotein, blood; electrophoretic separation and quantitation |
| 83701 | Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation) |
| 83704 | Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed |
| 0119U | Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events |
| 0052U | Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation |
| 82610 | Cystatin C |
| 81479 | Unlisted molecular pathology procedure |
| 83880 | Natriuretic peptide |
| No codes listed |
Provider Requirements, Prior Authorization, and Billing Guidance
Provider Authorization, Billing, and Documentation Requirements
Prior authorization is required for all unlisted genetic testing CPT codes (including 81479 when used for cardiovascular risk panels) so that the service rendered and medical necessity can be determined. Laboratories are not permitted to obtain or facilitate prior authorization on behalf of the ordering physician; only the ordering physician may participate in authorization, appeals, or related administrative processes. Unauthorized laboratory-obtained authorizations or facilitation by a lab or third party is a violation and may result in termination from the BCBSRI network. If a participating laboratory provides a service that was not authorized, the service will be denied and the financial liability will rest with the laboratory — the member must not be billed.
- All unlisted genetic CPTs require prior authorization.
- When no specific CPT exists for a cardiovascular risk panel, file 81479 (Unlisted molecular pathology procedure) and obtain prior authorization.
- BNP (natriuretic peptide) testing (CPT 83880) must be interpreted in conjunction with standard diagnostic tests, medical history and clinical findings; BNP may be covered but not separately reimbursed in certain acute-care or ED evaluations.
- Covered assays with specific CPTs (e.g., 85384, 85385, 83700, 83701, 83704, 83880) must be filed with appropriate covered ICD-10 codes when required.
- Certain listed CPT codes are not covered/medically necessary for Medicare Advantage and Commercial Products (e.g., 83695, 83698, 83722); claims for these codes will be denied as not medically necessary.
- Documentation guidance: submit clinical rationale, relevant medical history, concurrent diagnostic test results, and the covered ICD-10 code(s) supporting medical necessity with prior authorization requests and claims.
- Member billing and denial risk: services determined not medically necessary or non-covered may be denied and may not be billed to the member unless the member was informed in advance and agreed in writing.
- Improper authorization facilitation (use of lab representatives or third parties to obtain authorization) will be treated as a violation and may result in severe action including termination from the provider network.
Clinical Background and Evidence Context
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality. Traditional risk assessment relies on clinical risk factors and standard lipid testing (eg, total cholesterol, LDL, HDL, triglycerides) and validated risk scores. Numerous additional lipid, inflammatory, metabolic, and genetic biomarkers and commercially available multi‑marker panels have been proposed to refine risk prediction; however, many of these nontraditional markers have not been shown to provide actionable information that improves outcomes beyond established assessment methods.
Key Terms and Biomarker Definitions
Policy Updates and Revision Notes
Fibrinogen testing (CPT 85384 - fibrinogen activity; CPT 85385 - fibrinogen antigen) added as covered for Medicare Advantage Plans and Commercial Products effective 2/1/2026.
Policy last reviewed on 2025-10-01 (administrative review date referenced in policy metadata).
Next scheduled review recorded as 2025-10-01 (document metadata).
Tests (CPT 82610, 83700, 83701, 83704) designated medically necessary when filed with a covered diagnosis (filing requirement clarified).
Lipoprotein(a) (CPT 83695), small dense LDL (CPT 83722), and Lp-PLA2 (CPT 83698) were designated not covered for Medicare Advantage Plans and not medically necessary for Commercial Products due to insufficient evidence.
B-type natriuretic peptide testing (CPT 83880) clarified as covered but not separately reimbursed when used with standard diagnostic evaluation of acute heart failure in acute-care settings.
Commercial multi-marker cardiovascular risk panels (including CPTs 0119U, 0052U and panels billed with 81479) designated not covered or not medically necessary due to insufficient evidence.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.